-
Mashup Score: 3Brain Cancer Hope: 19.9 Month Median Survival with New Combo - 3 month(s) ago
Combining olaptesed pegol with bevacizumab and radiotherapy showed a 10-fold improvement in survival rate compared with the standard-of-care among patients with glioblastoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Brain Cancer Hope: 19.9 Month Median Survival with New Combo - 3 month(s) ago
Combining olaptesed pegol with bevacizumab and radiotherapy showed a 10-fold improvement in survival rate compared with the standard-of-care among patients with glioblastoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9
Purpose Glioblastomas, the most common primary malignant brain tumors in adults, still hold poor prognosis. Corticosteroids, such as dexamethasone, are usually prescribed to reduce peritumoral edema and limit neurological symptoms, although potential detrimental effects of these drugs have been described. The present meta-analysis aimed to explore the association of dexamethasone with overall…
Source: link.springer.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Olaptesed Pegol Continues to Improve Survival in Glioblastoma - 5 month(s) ago
The median overall survival at 19 months of patients with glioblastoma continues to benefit from treatment with olaptesed pegol plus radiation and bevacizumab.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0DOC1021 Gains FDA Fast Track Designation in Glioblastoma Multiforme - 7 month(s) ago
A fast track designation has been granted to DOC1021 by the FDA for the treatment of patients with glioblastoma multiforme.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Dr. Fahar Merchant Discusses a Treatment to Combat Glioblastoma - 8 month(s) ago
Home > Oncology > Dr. Fahar Merchant Discusses a Treatment to Combat Glioblastoma Medicenna, a clinical-stage immunotherapy company, has made significant progress in the development of MDNA11 and MDNA55, which utilize engineered interleukins, known as Superkines, to modulate the i mmune system and combat challenging diseases like recurrent glioblastoma multiforme—an invariably fatal form of brain cancer—and other end-stage cancers. MDNA55, an empowered Superkine, delivers a potent bacterial toxin directly
Source: www.docwirenews.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Could VAL-083 Address Modest Treatment Efficacy in Glioblastoma? - 8 month(s) ago
Experts believe VAL-083 has the potential to change the way oncologists treat glioblastoma in the future.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Combination Treatment May Help Some Patients With Glioblastoma - 8 month(s) ago
Combining immunotherapy with a tumor-targeted virus may help extend survival in some patients with recurrent glioblastoma, according to the results of a trial published in Nature Medicine.
Source: news.feinberg.northwestern.eduCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
In an interview with Targeted Oncology, Ahmad Ozair, MBBS, discussed treatments for glioblastoma and a trial evaluating surgically targeted radiation therapy in this patient population.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Gallium Maltolate Gains FDA ODD for Pediatric GBM - 10 month(s) ago
Gallium maltolate now has been granted an orphan drug designation for adult and pediatric patients with glioblastoma multiforme.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Olaptesed pegol + bevacizumab and radiotherapy delivered an improved median overall survival of 19.9 months in patients with newly diagnosed glioblastoma, according to the phase 1/2 GLORIA study. #GBM https://t.co/sHAnZkrlYb